These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8427659)

  • 1. Defective 3,4-dihydroxyphenylalanine decarboxylation to dopamine in hydralazine-treated hypertensive patients may be pyridoxine remediable.
    Shigetomi S; Kuchel O
    Am J Hypertens; 1993 Jan; 6(1):33-40. PubMed ID: 8427659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic abnormalities in hypertension associated with moderate renal insufficiency.
    Kuchel OG; Shigetomi S
    Hypertension; 1994 Jan; 23(1 Suppl):I240-5. PubMed ID: 8282367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective dopamine generation from dihydroxyphenylalanine in stable essential hypertensive patients.
    Kuchel O; Shigetomi S
    Hypertension; 1992 Jun; 19(6 Pt 2):634-8. PubMed ID: 1592460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sodium intake increases the urinary excretion of L-3,4-dihydroxyphenylalanine but fails to alter the urinary excretion of dopamine and amine metabolites in Wistar rats.
    Vieira-Coelho MA; Pestana M; Soares-da-Silva P
    Gen Pharmacol; 1996 Dec; 27(8):1421-7. PubMed ID: 9304419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic abnormalities in borderline essential hypertensive patients.
    Shigetomi S; Buu NT; Kuchel O
    Hypertension; 1991 Jun; 17(6 Pt 2):997-1002. PubMed ID: 1904403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model.
    Soares-da-Silva P; Pestana M; Vieira-Coelho MA; Fernandes MH; Albino-Teixeira A
    Br J Pharmacol; 1995 Apr; 114(7):1403-13. PubMed ID: 7541690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary excretion of dihydroxyphenylalanine and dopamine during alterations of dietary salt intake in humans.
    Goldstein DS; Stull R; Eisenhofer G; Gill JR
    Clin Sci (Lond); 1989 May; 76(5):517-22. PubMed ID: 2498027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat.
    Pestana M; Vieira-Coelho MA; Pinto-do-O PC; Fernandes MH; Soares-da-Silva P
    Br J Pharmacol; 1995 Aug; 115(8):1349-58. PubMed ID: 8564191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of protein ingestion on urinary dopamine excretion. Evidence for the functional importance of renal decarboxylation of circulating 3,4-dihydroxyphenylalanine in man.
    Williams M; Young JB; Rosa RM; Gunn S; Epstein FH; Landsberg L
    J Clin Invest; 1986 Dec; 78(6):1687-93. PubMed ID: 3097077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivation of urinary dopamine from plasma dopa.
    Zimlichman R; Levinson PD; Kelly G; Stull R; Keiser HR; Goldstein DS
    Clin Sci (Lond); 1988 Nov; 75(5):515-20. PubMed ID: 3151165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid.
    Eldrup E; Møller SE; Andreasen J; Christensen NJ
    Clin Sci (Lond); 1997 Apr; 92(4):423-30. PubMed ID: 9176043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma.
    Eldrup E; Clausen N; Scherling B; Schmiegelow K
    Scand J Clin Lab Invest; 2001; 61(6):479-90. PubMed ID: 11681538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High urinary dopa and low urinary dopamine-to-dopa ratio in salt-sensitive hypertension.
    Gill JR; Grossman E; Goldstein DS
    Hypertension; 1991 Nov; 18(5):614-21. PubMed ID: 1937664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary dopamine and renal handling of L-DOPA in fasted spontaneously hypertensive rats.
    Dantonello TM; Küster E; Mühlbauer B
    Kidney Blood Press Res; 1998; 21(6):438-44. PubMed ID: 9933829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal dopaminergic mechanisms in renal parenchymal diseases and hypertension.
    Pestana M; Jardim H; Correia F; Vieira-Coelho MA; Soares-da-Silva P
    Nephrol Dial Transplant; 2001; 16 Suppl 1():53-9. PubMed ID: 11369822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decreased tubular uptake of dopa results in defective renal dopamine production in aged rats.
    Armando I; Nowicki S; Aguirre J; Barontini M
    Am J Physiol; 1995 Jun; 268(6 Pt 2):F1087-92. PubMed ID: 7611449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats.
    Kvetnanský R; Goldstein DS; Weise VK; Holmes C; Szemeredi K; Bagdy G; Kopin IJ
    J Neurochem; 1992 Jun; 58(6):2296-302. PubMed ID: 1573408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans.
    Wolfovitz E; Grossman E; Folio CJ; Keiser HR; Kopin IJ; Goldstein DS
    Clin Sci (Lond); 1993 May; 84(5):549-57. PubMed ID: 8504632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.